

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Docetaxel

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Taxotere (docetaxel)

APPROVAL CRITERIA

Requests for docetaxel (Taxotere) may be approved if the individual has *f any* of the following conditions:

- I. Bladder cancer(NCCN 2A); **OR**
- II. Bone cancer (NCCN 2A):
 - A. Ewing's sarcoma; **OR**
 - B. Osteosarcoma;
- III. Breast cancer; **OR**
- IV. Esophageal and esophagogastric junction cancers (NCCN 2A); **OR**
- V. Gastric (stomach) adenocarcinoma; **OR**
- VI. Head and neck cancer; **OR**
- VII. Lung cancer (non-small cell lung cancer and small cell lung cancer [NCCN 2A]); **OR**
- VIII. Occult primary tumors (cancer of unknown primary) (NCCN 2A):
 - A. Adenocarcinoma; **OR**
 - B. Squamous cell carcinoma;
- IX. Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer (NCCN 2A); **OR**
- X. Penile cancer; **OR**
- XI. Prostate cancer; **OR**
- XII. Soft tissue carcinoma (NCCN 2A); **OR**
- XIII. Thyroid Carcinoma - Anaplastic Carcinoma, used in combination with doxorubicin; **OR**
- XIV. Uterine neoplasms (NCCN 2A).

Requests for docetaxel (Taxotere) may not be approved when the above criteria are not met and for all other indications.

Note:

Docetaxel has a black box warning regarding treatment mortality increases with abnormal liver function, at higher doses, and in those with NSCLC and prior platinum-based therapy receiving

CRX-ALL-0540-20

PAGE 1 of 2 04/20/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

docetaxel at 100 mg/m². Docetaxel should not be given if bilirubin is greater than upper limit of normal (ULN) or if AST and/or ALT are greater than 1.5 time ULN concomitant with alkaline phosphatase > 2.5 ULM. Liver function tests (LFTs) should be obtained before each treatment cycle. Docetaxel should not be given if neutrophil counts are less than 1,500 cells/mm³.

Key References:

1. Aldrich JD, Raghav KPS, Varadhachary GR, et al. Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma. *Oncologist*. 2019;24:e384-6.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 3, 2020.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed January 3, 2020.
 - a. Bladder cancer. V1.2020. Revised November 27, 2019.
 - b. Bone cancer. V1.2020. Revised August 12, 2019.
 - c. Breast cancer. V3.2019. Revised September 6, 2019.
 - d. Esophageal and esophagogastric junction cancers. V4.2019. Revised December 20, 2019.
 - e. Gastric cancer. V4.2019. Revised December 20, 2019.
 - f. Head and neck cancers. V3.2019. Revised September 16, 2019.
 - g. Non-Small Cell Lung Cancer. V2.2020. Revised December 23, 2019.
 - h. Occult primary. V1.2020. Revised October 14, 2019.
 - i. Ovarian cancer. V3.2019. Revised November 26, 2019.
 - j. Prostate cancer. V4.2019. Revised August 19, 2019.
 - k. Small Bowel Adenocarcinoma. V1.2020. Revised July 30, 2019.
 - l. Small cell lung cancer. V2.2020. Revised November 15, 2019.
 - m. Soft tissue sarcoma. V4.2019. Revised September 12, 2019.
 - n. Thyroid carcinoma. V2.2019. Revised September 16, 2019.
 - o. Uterine neoplasms. V5.2019. Revised December 23, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.